The Retrospective Cohort Study for Survival Rate in Patients with Advanced Hepatocellular Carcinoma Receiving Radiotherapy or Palliative Care

Overview

Journal Korean J Hepatol

Specialty Gastroenterology

Date 2011 Nov 22

PMID 22102385

Citations 6

Authors

Hyuk Soo Eun

Min Jung Kim

Hye Jin Kim

Kwang Hun Ko

Hee Seok Moon

Eaum Seok Lee

Seok Hyun Kim

Heon Young Lee

Byung Seok Lee

Affiliations

Soon will be listed here.

Abstract

Background/aims: This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).

Methods: From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.

Results: Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.

Conclusions: We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Citing Articles

Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology.

Ekanayaka S, Luke N, Thilakarathne S, Dassanayake A, Gunetilleke M, Niriella M Indian J Gastroenterol. 2024; 43(6):1176-1183.

PMID: 38985413 DOI: 10.1007/s12664-024-01636-9.

Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Yu J, Park H World J Gastroenterol. 2016; 22(30):6851-63.

PMID: 27570422 PMC: 4974584. DOI: 10.3748/wjg.v22.i30.6851.

Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Park H, Yu J, Cheng J, Zeng Z, Hong J, Wang M Liver Cancer. 2016; 5(3):162-74.

PMID: 27493892 PMC: 4960352. DOI: 10.1159/000367766.

Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Slotta J, Kollmar O, Ellenrieder V, Ghadimi B, Homayounfar K World J Hepatol. 2015; 7(9):1168-83.

PMID: 26019733 PMC: 4438492. DOI: 10.4254/wjh.v7.i9.1168.

2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Korean J Radiol. 2015; 16(3):465-522.

PMID: 25995680 PMC: 4435981. DOI: 10.3348/kjr.2015.16.3.465.

References

Kim T, Kim D, Park J, Kim Y, Kim S, Park H . Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol. 2006; 29(6):568-75. DOI: 10.1097/01.coc.0000239147.60196.11. View

Hawkins M, Dawson L . Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006; 106(8):1653-63. DOI: 10.1002/cncr.21811. View

Dhir V, Swaroop V, Mohandas K, Dinshaw K, Desai D, Nagral A . Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. Am J Clin Oncol. 1992; 15(4):304-7. DOI: 10.1097/00000421-199208000-00005. View

Cheng S, Lin Y, Chuang V, Yang P, Cheng J, Huang A . A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 1999; 14(10):1025-33. DOI: 10.1046/j.1440-1746.1999.01994.x. View

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Pompili M, Rapaccini G, Covino M, Pignataro G, Caturelli E, Siena D . Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer. 2001; 92(1):126-35. DOI: 10.1002/1097-0142(20010701)92:1<126::aid-cncr1300>3.0.co;2-v. View

Seong J, Keum K, Han K, Lee D, Lee J, Chon C . Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43(2):393-7. DOI: 10.1016/s0360-3016(98)00415-5. View

Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G . Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer. 1995; 76(10):1737-46. DOI: 10.1002/1097-0142(19951115)76:10<1737::aid-cncr2820761010>3.0.co;2-p. View

Mori W . Cirrhosis and primary cancer of the liver. Comparative study in Tokyo and Cincinnati. Cancer. 1967; 20(5):627-31. DOI: 10.1002/1097-0142(1967)20:5<627::aid-cncr2820200509>3.0.co;2-4. View

10.

Zeng Z, Tang Z, Fan J, Qin L, Ye S, Zhou J . Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys. 2005; 63(4):1067-76. DOI: 10.1016/j.ijrobp.2005.03.058. View

11.

. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009; 15(3):391-423. DOI: 10.3350/kjhep.2009.15.3.391. View

12.

Seong J, Park H, Han K, Chon C . Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys. 2003; 55(2):329-36. DOI: 10.1016/s0360-3016(02)03929-9. View

13.

Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B . Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005; 54(3):411-8. PMC: 1774422. DOI: 10.1136/gut.2004.048124. View

14.

Park W, Lim D, Paik S, Koh K, Choi M, Park C . Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61(4):1143-50. DOI: 10.1016/j.ijrobp.2004.08.028. View

15.

Meng M, Cui Y, Lu Y, She B, Chen Y, Guan Y . Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2008; 92(2):184-94. DOI: 10.1016/j.radonc.2008.11.002. View

16.

Dawson L, Ten Haken R . Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005; 15(4):279-83. DOI: 10.1016/j.semradonc.2005.04.005. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Lawrence T, Dworzanin L, Andrews J, Ten Haken R, Wollner I, Lichter A . Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys. 1991; 20(3):555-61. DOI: 10.1016/0360-3016(91)90069-g. View

19.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

20.

Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y . Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer. 1990; 66(10):2174-9. DOI: 10.1002/1097-0142(19901115)66:10<2174::aid-cncr2820661022>3.0.co;2-a. View